MABS’s lead biologic agent, MABS-139, a pan-RNA Degrader (pRNAD) protein, has completed Phase 1 trial in advanced, refractory solid tumor indications. The company expects to initiate new Phase 1b dose confirmation study in patients with colon, ovarian, lung and prostate cancers in 2024. MABS also has preclinical RNAD and ADC programs targeting cell-surface antigens that are overexpressed on cancer cells